Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug candidate takes on stubborn lung infection

NCT ID NCT06004037

Completed Disease control Sponsor: LigaChem Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether adding delpazolid to standard treatment can reduce bacterial levels in people with hard-to-treat Mycobacterium abscessus lung infections. Participants take delpazolid tablets daily for 12 weeks, with the option to continue up to one year if there is clinical benefit. The trial enrolls adults whose infection persists despite at least six months of guideline-based therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Delpazolid (also called LCB01-0371)
What this could lead to
If successful, delpazolid could offer a new add-on option for people with hard-to-treat Mycobacterium abscessus lung infections, potentially improving bacterial clearance.
What could go wrong
This is a small, early-phase trial (24 participants) with no placebo group, so results may not be definitive. The drug may cause side effects or fail to show meaningful benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM ABSCESSUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycobacterial infectious disease Mycobacterium Infections, Nontuberculous pulmonary non-tuberculous mycobacterial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOBACTERIUM ABSCESSUS INFECTION NONTUBERCULOUS MYCOBACTERIUM INFECTION

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Bundang Seoul National University Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.